Quintrio
Home

Stock overview

Radiopharm Theranostics Limited American Depositary Shares

RADX

Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.653 – $0.757
Volume 29,944
Market cap $12M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for RADX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for RADX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

Radiopharm Theranostics received FDA alignment on a pivotal Phase 3 trial design for RAD101, a novel imaging agent for detecting brain metastases. The single multicenter trial will enroll approximately 280 patients and is substantially smaller than historical imaging studies, reflecting significant unmet medical need. The company expects to initiate the trial in the first half of 2027 with manufacturing support from Siemens Healthineers.

GlobeNewswire Inc.

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, a brain metastases imaging agent that demonstrated 93% concordance with MRI. The company is preparing to initiate a pivotal Phase 3 trial in 1Q27 and has secured a manufacturing partnership with Siemens Healthineers. Additionally, Radiopharm reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 to the fourth dosing cohort in its HER2+ solid tumor study.

GlobeNewswire Inc.

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics announced dosing of the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) at 70 mCi, following a positive recommendation from the Safety and Monitoring Committee. RV-01 is a 177Lutetium-tagged monoclonal antibody targeting B7-H3 in patients with B7-H3 expressing solid tumors, developed through a joint venture with MD Anderson Cancer Center.

GlobeNewswire Inc.

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics completed enrollment in its Phase 2b trial for RAD 101, an imaging agent for brain metastases, with interim data showing 90% concordance with MRI. The company also presented Phase 0/1 data for RAD 202 showing favorable safety and tumor uptake, received DSMC approval to advance to the next dose level, and initiated two new First-In-Human trials for radiotherapeutic assets RV-01 and RAD 402. Cash position declined to $19.2 million from $34.5 million in the prior quarter.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.